⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

PPLPHARMA - Technical Analysis with Chart Patterns & Indicators

← Back to List

⭐ Rating: 3.2

Last Updated Time : 12 Sept 26, 06:56 pm

Key Parameters

⭐ Technical Rating: 3.2

RSI51.1
MACD4.28
DMA 50202 ₹
DMA 200184 ₹
High / Low232 ₹
Low price132 ₹
High price232 ₹
52w Index79.3 %
Show all parameters (20 more)
Stock CodePPLPHARMA
Market Cap28,137 Cr.
Current Price211 ₹
Stock P/E36.3
Book Value61.2 ₹
Dividend Yield0.07 %
ROCE11.8 %
ROE9.84 %
Face Value10.0 ₹
Chg in FII Hold-17.7 %
Chg in DII Hold-1.04 %
PAT Qtr113 Cr.
PAT Prev Qtr313 Cr.
Volume37,34,274
Avg Vol 1Wk79,62,798
PEG Ratio0.30
Debt to equity0.10
Qtr Profit Var0.30 %
EPS5.27 ₹
Industry PE34.6

🧾 Chart Verdict

Short-term entry zones would be between 208 ₹ - 213 ₹ based on the current price action and resistance levels observed around 232₹. An exit strategy could be triggered at the next support level around 195 ₹, or if the RSI dips below 48 while maintaining a high volume trend. Overall, while the momentum is positive, the elevated valuation warrants careful monitoring for potential reversals.

✅ Positive

The price is currently trading above the 200-day moving average (DMA 200) and exhibiting a period of sustained upward momentum as indicated by the RSI, suggesting potential for further gains. Furthermore, the volume has been consistently high over the past week, reinforcing this upward trend.

⚠️ Limitation

Despite the positive momentum, the elevated P/E ratio of 36.3 compared to the industry average of 34.6 indicates a premium valuation which could present downside risk if growth expectations aren’t met. The recent ‘Sell’ rating from MarketsMOJO adds a layer of caution, and a potential pullback remains possible should sentiment shift negatively.

📉 Company Negative News

MarketsMOJO has issued a “Sell” rating for Piramal Pharma, suggesting investors may want to consider exiting their positions or remain cautious. Business Standard reports an uptick in volumes at Pfizer Ltd., which could be diverting attention away from PPLPHARMA.

📈 Company Positive News

The recent quarterly profit increase of 113 Cr. represents solid performance and demonstrates the company's financial strength, potentially supporting continued price appreciation if maintained. MarketsMojo’s analysis highlighted a CDMO recovery lifting EBITDA, offering a positive sector-specific narrative that could bolster investor confidence.

🏭 Industry

The pharmaceutical sector is currently experiencing recovery driven by increased demand for contract development and manufacturing services (CDMO). Industry PE ratios are relatively high reflecting the growth potential of this segment; however, recent ratings suggest caution within this sector.

Choose Technical Analysis or Fundamental Analysis above to load it.

How PPLPHARMA Rates Across All Strategies

★ 2.5
Initiate a long position at 205 ₹ – targeting a stop-loss order just…
★ 2.3
Buy Price: 205 ₹.
★ 2.3
An ideal entry zone would be between 195 ₹ and 205 ₹, capitalizing on…
★ 2.8
We recommend an entry zone around 190-200 ₹, predicated on the curren…

NIFTY 50 · Technical

NEXT 50 · Technical

MIDCAP · Technical

SMALLCAP · Technical